Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin PK in Peritoneal Dialysis
NCT02940730Phase 4Completed
- Sponsor
- University of Colorado Denver
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalbavancin in infectious peritonitis (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Dalbavancin Plasma Area Under the Curve at 14 days and Dalbavancin Peritoneal Fluid Area Under the Curve at 14 days. Started May 2017; status: completed.
02
Drugs
dalbavancin
03
Conditions
infectious peritonitis
Beyond the preview
Go deeper on NCT02940730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940730.